BioFocus and Ono Sign a Drug Discovery Agreement in the Field of CNS Disorders
News Oct 08, 2012
Galapagos NV has announced that its service division BioFocus and Ono Pharmaceutical Co., Ltd. (Osaka Japan) have signed a new collaboration agreement, focused on discovering novel drugs in the field of CNS disorders.
Under the new agreement, BioFocus will use its drug discovery platform to deliver leads and clinical candidates for its client. Financial details were undisclosed.
“We are delighted to have this new agreement, which is the first drug discovery program with this, a most valued, client” said Dr. Chris Newton, SVP Galapagos Services and Managing Director of BioFocus.
Dr. Newton continued, “This project plays to BioFocus historic strengths and the expanding breadth and depth of this partnership is testament to a tried and trusted relationship.”
Kazuhito Kawabata, Ph.D., Member of the Board of Directors, Executive Officer and Executive Director, Discovery and Research of Ono commented: “We have the highest regard for the BioFocus’ comprehensive drug discovery platform. This collaboration will strengthen Ono’s drug discovery capability in the field of CNS disorders with significant unmet medical needs and we are expecting that innovative drugs will be created through this collaboration.”
New Partnership to Provide Bioanalytical and DMPK ServicesNews
Concept Life Sciences, the integrated drug discovery, development and analytical services company, and Alderley Analytical, bioanalytical Contract Research Organisation (CRO), today announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.
Toothpaste Ingredient Could Help Fight Drug-Resistant MalariaNews
An ingredient commonly found in toothpaste could be employed as an anti-malarial drug against strains of malaria parasite that have grown resistant to one of the currently-used drugs.READ MORE
Small Compound Able to Stave Tumor and Stop its GrowthNews
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital nutrient glutamine.READ MORE